Announcements

We are pleased to share an interview with Dr. Sveinung Wergeland Sørbye, who has been recognized as a JCM Exceptional Reviewer 2025. In this interview, Dr. Sveinung Wergeland Sørbye discusses the benefits of open access publishing and shares his perspective on the peer review process. He also offers valuable insights into AI tools in peer review. We invite you to read the full interview and learn more about Dr. Sveinung Wergeland Sørbye’s perspectives on peer review and scientific publishing.

1. Could you briefly introduce yourself and tell us about your current research focus?

I am Sveinung Wergeland Sørbye, MD, PhD, a senior consultant pathologist at the Department of Clinical Pathology, University Hospital of North Norway (UNN), in Tromsø, Norway. My work combines diagnostic pathology, cervical cancer prevention, and clinical research, with a particular focus on how pathology and laboratory medicine can support more precise and effective patient care.

My current research focuses mainly on HPV-related disease prevention and risk stratification in cervical screening. This includes studies on HPV testing, cervical cytology, histological assessment of cervical biopsies, post-treatment follow-up after conization, and the potential role of HPV vaccination in women treated for cervical precancer. I am also involved in projects evaluating genotype-specific HPV mRNA testing, real-world screening data, and the implementation of digital pathology and artificial intelligence in diagnostic practice. Across these areas, my main goal is to generate evidence that is clinically relevant, methodologically robust, and directly applicable to patient management and public health.

2. What key aspects do you prioritize when reviewing a manuscript? How do you evaluate the validity and translational potential of clinical study?

When I review a manuscript, I first look at whether the introduction clearly defines the clinical problem, the knowledge gap, and the study aim in the context of existing evidence. Many of the papers I assess are within my own field—HPV, cervical screening, precancer, and cancer prevention—so I pay close attention to whether the authors have framed the research question precisely and supported it with relevant primary references rather than relying too heavily on secondary citations.

To evaluate validity, I focus on whether the study design is appropriate for the research question, whether the inclusion criteria and endpoints are clearly defined, and whether the methods are sufficiently detailed and reproducible. I also consider sample size, risk of bias, confounding, follow-up completeness, and whether the statistical analyses match the design and data structure. Just as importantly, I examine whether the conclusions are proportional to the results.

For translational potential, I ask a simple question: Will these findings meaningfully improve clinical decision-making, patient stratification, diagnostic accuracy, treatment, or follow-up in real-world practice? A strong clinical study should not only be methodologically sound but also relevant, interpretable, and applicable beyond the study setting.

3. How do you balance encouraging innovation with ensuring methodological rigor and ethical compliance? Could you share an example from your review experience?

I try to balance innovation and rigor by being open to new ideas while applying the same core standards to every manuscript. Novelty alone is not enough. Study may be highly innovative, but it still needs a sound design, clearly defined endpoints, appropriate comparators, transparent methods, and conclusions that do not go beyond the data. I also look carefully at ethical aspects such as informed consent, patient confidentiality, approval by the relevant ethics committee, and whether the proposed clinical use is justified by the evidence presented.

In my view, the best reviews do not discourage innovation; they help make it more credible and clinically useful. For example, I have reviewed studies presenting new diagnostic or triage approaches with clear potential, but where the initial manuscript overstated the immediate clinical implications. In such cases, I typically encourage the authors to keep the innovative concept, while strengthening the methodological description, clarifying validation, acknowledging limitations more explicitly, and moderating the conclusions when implementation data are still limited. That way, promising research can move forward without compromising scientific integrity or patient trust.

4. What advice would you give to early career clinicians or researchers who are beginning to participate in peer review?

My advice to early career clinicians and researchers is to see peer review not only as a responsibility but also as an important part of academic development. If you want to publish scientific papers, you should also be willing to contribute to the review process. Peer review is one of the ways the scientific community maintains quality, credibility, and fairness.

It is also important to remember that you do not need to identify every weakness in a manuscript to provide a valuable review. Most papers are evaluated by two or more reviewers, and each reviewer may notice different strengths and limitations. Even if you focus on only some aspects—such as the clinical relevance, the clarity of the research question, the appropriateness of the methods, or the interpretation of the results—you may still identify something important that others have overlooked.

I would also encourage early career reviewers to treat peer review as a learning opportunity. I have found it very useful to compare my own review with the comments from the other reviewers and the editor’s decision. This helps refine judgment over time and improves both reviewing skills and one’s own scientific writing.

5. Beyond correcting errors, what unique contribution do you think a strong peer review brings to clinical science and patient care?

Beyond correcting errors, a strong peer review helps place a study in the right scientific and clinical context. This is especially important in clinical medicine, where the implications may affect guidelines, patient counseling, screening strategies, diagnostic pathways, or treatment decisions. A reviewer should not only assess whether the data are internally consistent but also whether the interpretation is aligned with the best available evidence and with how care is actually delivered in real-world settings.

In my own field—HPV vaccination, HPV testing, screening, triage, and cervical cancer prevention—I know the literature very well and can often help authors position their findings more accurately within previous research. Sometimes this means recommending additional key references or asking the authors to discuss their results in light of major evidence-based developments. For example, when a manuscript addresses cervical cancer screening, it should take into account that the WHO recommends HPV testing rather than cytology or VIA as the primary screening method. It is also important to consider implementation: organized call-recall screening programs, school-based HPV vaccination, and opt-out self-sampling strategies often have a greater public health impact than information campaigns alone. In that way, strong peer review improves not only the manuscript but also its relevance for patient care and public health.

6. Based on your review experience, which emerging topics or methodologies do you believe will be particularly influential in the coming years?

I can mainly answer from the perspective of my own field, cervical cancer prevention and screening. In primary screening, HPV DNA testing has very high sensitivity, but its specificity is more limited. Many countries that have adopted HPV-based screening still rely on cervical cytology for triage. However, cytology is subjective, labor-intensive, and has limited reproducibility, which means that both sensitivity and specificity can vary across settings and observers.

For that reason, I believe the most influential developments in the coming years will be objective molecular and biomarker-based triage methods. These include extended HPV genotyping, p16/Ki67 dual staining, genotype-specific HPV mRNA testing, and methylation markers. These approaches have the potential to provide more reproducible and clinically meaningful risk stratification than cytology alone.

I also think these methods will become particularly important in the era of self-sampling. As self-sampling expands, there is a growing need for triage strategies that do not depend on a conventional cytology sample or subjective microscopic interpretation. AI-based tools may improve cervical cytology, but in the longer term, I believe biomarker-based triage will have the greatest clinical impact.

7. JCM is an open access journal. How do you see open access shaping the dissemination and impact of clinical research?

I believe open access is very important because it makes scientific publications and new clinical research findings available to everyone, not only to readers at institutions with expensive journal subscriptions. In medicine, this matters greatly. Clinicians, researchers, policymakers, and sometimes even patients can benefit from direct access to new evidence.

Open access can also help reduce the gap between high-resource and lower-resource settings. If important studies on diagnostics, screening, treatment, or prevention are freely available, they are more likely to be read, discussed, and applied in practice across different healthcare systems. This can strengthen both scientific exchange and the real-world impact of research.

At its best, open access increases visibility, accelerates dissemination, and supports faster translation of evidence into patient care. Of course, accessibility alone is not enough. The quality of the research and the rigor of peer review remain essential. But when strong studies are made openly available, their potential to inform clinical decisions, guidelines, and future research is clearly greater.

8. How do you manage your time between clinical duties, research, and peer review? What motivates you to continue contributing as a reviewer?

Balancing clinical work, research, and peer review is challenging. I work as a pathologist in a public hospital with full-time diagnostic responsibilities, so most of my research and peer-review activities take place in my personal time, mainly in the evenings and on weekends. In practice, this means I have to prioritize carefully. At times, I need to focus on my own research projects and manuscripts, but I still try to contribute regularly as a reviewer and often complete one or two reviews on a weekend.

What motivates me is the sense that peer review is a meaningful contribution to a field where good science can make a real difference. Cervical cancer is largely preventable through HPV vaccination, screening, and treatment of precancerous lesions, yet it still causes a major global burden, especially in low- and middle-income countries. By helping improve the quality, clarity, and clinical relevance of submitted manuscripts, I feel that I can contribute—indirectly but genuinely—to better prevention and patient outcomes.

Peer review also helps me stay updated in a rapidly evolving field. Despite the time pressure, I continue reviewing because I see it as part of my professional responsibility as both a clinician and a researcher.

9. How do you view the role of a reviewer in shaping the quality and integrity of published research?

I view the reviewer as an important safeguard for both the quality and integrity of published research. Peer-reviewed manuscripts are still regarded as the gold standard in scientific publishing, not because the process is perfect, but because independent expert evaluation helps identify weaknesses before the work enters the literature and may influence clinical practice, future research, or health policy.

A good reviewer helps ensure that the research question is clear, the methods are appropriate, the analyses are sound, the conclusions are supported by the data, and the limitations are acknowledged honestly. Just as importantly, reviewers help detect overinterpretation, selective reporting, poor referencing, or claims that are not justified by the evidence.

I believe that my own contribution as a reviewer improves the overall quality of manuscripts by making them more accurate, more balanced, and more clinically relevant. In that way, peer review not only improves individual papers; it also helps protect trust in the scientific literature as a whole.

10. What are your perspectives on the impact of AI tools on integrity, efficiency, and future of peer review?

AI tools can improve both the efficiency and the consistency of scientific publishing, especially if journals integrate them in a structured and transparent way. I believe journals should offer authors AI-based support during submission to help with formatting, spelling, grammar, clarity, flow, and compliance with formal journal requirements. Such tools could also check whether in-text citations match the reference list and whether the references are formatted correctly. If authors could use these tools directly on the journal’s submission platform before final submission, the process from submission to review, acceptance, and publication could become faster and more efficient.

As a non-native English-speaking researcher, I have experienced how useful AI can be for improving scientific writing. In the past, professional copyediting was often necessary before submission. Today, tools such as ChatGPT can greatly reduce that need. As a reviewer, I therefore increasingly expect manuscripts to be written in clear and polished English.

At the same time, AI should support, not replace, human scientific judgment. It can improve efficiency, but integrity still depends on authors, reviewers, and editors who critically assess the science, the interpretation, and the ethical standards behind the manuscript. AI tools must also be used with caution, because they may introduce fabricated references, miss clinical nuance, or raise confidentiality concerns if unpublished manuscripts are uploaded to external systems.

The Journal of Clinical Medicine (JCM, ISSN: 2077-0383) held the Editorial Board Meeting for the “Infectious Diseases” Section on 17 March 2026. The meeting was hosted by the Section’s Editor-in-Chief, Prof. Dr. Robert Flisiak, with seven Editorial Board Members in attendance to discuss the development of the “Infectious Diseases” Section. We sincerely appreciate the valuable insights and constructive suggestions shared by members. We also welcome additional members to participate in our future online meetings and conference booths. In addition, we encourage members to share their suggestions and ideas at any time, and welcome further communication with the JCM Editorial Office (jcm@mdpi.com) or Journal Relations (jr-jcm@mdpi.com). We look forward to continued collaboration to advance the development of the “Infectious Diseases” Section and promote the dissemination of clinical and infectious disease knowledge.

The meeting commenced with an overview presentation covering key information about the journal and its “Infectious Diseases” Section, as detailed below:

• The journal’s performance data, distribution of scholars, editorial procedure details, and paper promotion channels;
• The journal’s diverse marketing activities, including conference sponsorship, free online webinars, virtual conferences (IOCCM 2026), social media accounts, awards, and society collaborations;
• Publication statistics of the “Infectious Diseases” Section over the past three years, the most popular publications and Special Issues within two years, the most active member, and an overview of the Section Members.

The following topics were discussed at this Editorial Board meeting:

• Members discussed future research directions and potential Special Issue topics, and recommended several topics;
• Members discussed the journal’s quality and editorial standards. We will continue to maintain a rigorous peer review process and adhere to ethical guidelines;
• Members are concerned about excessive AI use in manuscript writing, and we have shared the journal’s relevant supervision and review standards.
• Members recommended improving the quality and formatting of tables in published articles.

Attendee list (ordered alphabetically):

• Dr. Daniel Scott-Algara, Institut Pasteur, France;
• Dr. Emanuele Pontali, Galliera Hospital, Italy;
• Prof. Dr. Hiroshi Nishiura, Kyoto University, Japan;
• Prof. Dr. Jean-Francois Timsit, ¹ APHP Bichat Hospital F, France; ² Université Paris Cité, France;
• Prof. Dr. Robert Flisiak (Section Editor-in-Chief), Medical University of Białystok, Poland;
• Dr. Samantha S. Soldan, Wistar Institute, USA;
• Dr. Wojciech Rozek, National Veterinary Research Institute, Poland;
• Dr. Yasmin Maor, ¹ Wolfson Medical Center, Israel; ² Tel Aviv University, Israel.

To access additional statistics for the “Infectious Diseases” Section, please click here.

We welcome you to participate in the free online conference, “The 4th International Online Conference on Clinical Medicine” (IOCCM 2026), which includes the “Infectious Diseases” topic. Abstract submissions for this conference are open until 7 August 2026.

For further details, please visit https://www.mdpi.com/journal/jcm/events.

As a pioneer in open access publishing, MDPI maintains rigorous publication standards. This mission relies on the dedication and expertise of our reviewers, who invest their time and knowledge to ensure the quality and integrity of the research we publish.

In 2025, over 209,000 reviewers contributed to the peer-review process at MDPI, providing more than 1.3 million review reports for our journals. To express our gratitude, MDPI’s Reviewer Recognition Program highlights reviewers across over 400 journals, featuring those who have assessed at least one manuscript and agreed to be acknowledged.

In addition, MDPI has identified its Top 1000 Reviewers of 2024 to recognize those whose expertise, dedication, and thoughtful evaluations were particularly outstanding.

Many journals have also established Outstanding Reviewer Awards to honor our reviewers’ commitment to publication excellence. Together with the Exceptional Reviewer List, we showcase the importance of reviewers’ work and their time and dedication.

These initiatives serve to express our deepest appreciation and gratitude towards the whole reviewer community. In recognition of their contributions, we also welcome new researchers to join this community. If you would like to contribute to open access publishing, learn more about the reviewers’ benefits and sign up to join us.

Conference: the Swiss Congress of Radiology 2026 (SCR’26)
Date: 28–30 May 2026
Place: Lausanne, Switzerland
Conference website: https://congress.sgr-ssr.ch/

We are pleased to announce that MDPI will be participating as an exhibitor at the Swiss Congress of Radiology 2026 (SCR’26), which will be held on from 28 to 30 May 2026, in the SwissTech Convention Center of the EPFL in Lausanne.

The Swiss Society of Radiology (SGR-SSR) and its associated societies (SGPR-SSRP, SSVIR, SSER, SSSR, SSRMP), as well as the SVMTR-ASTRM (Swiss Association of Radiographers) and the SGNM-SSMN (Swiss Society of Nuclear Medicine), are making a great effort to develop an attractive programme over three days. It includes many educational and scientific sessions, exciting lectures covering the entire spectrum of diagnostic and interventional radiology, and more dedicated sessions for each subspeciality. For this, renowned national and international speakers have been invited.

As part of our commitment to supporting high-quality research in these fields, MDPI is proud to sponsor the event through the participation of the following journals:

• Diagnostics;
• JCM;
• Tomography;
• Uro;
• Biophysica;
• Radiation.

Our editorial team will be available on-site and would be delighted to meet with attendees. If you are attending the conference, feel free to stop by our booth to learn more about our open access publishing opportunities, ongoing Special Issues, and how we support researchers in advancing their work.

We look forward to meeting you in Lausanne!

Tuberculosis is a disease that is both preventable and treatable, significantly affecting people’s health and quality of life worldwide. Every year, we commemorate World Tuberculosis Day to raise public awareness of the devastating health, social, and economic consequences of tuberculosis (TB) and to intensify efforts to end the global TB epidemic. The date signifies the day in 1882 when Dr. Robert Koch announced his discovery of the bacterium responsible for TB, which paved the way for diagnosing and curing this disease.

The theme of World TB Day 2026, “Yes! We can End TB! Led by Countries, Powered by People”, is a bold call to action and a message of hope, affirming that it is possible to get back on track and turn the tide on the TB epidemic, even in a challenging global environment. With decisive country leadership, increased domestic and international investment, rapid uptake of new WHO recommendations and innovations, accelerated action, and strong multisectoral collaboration, ending TB is not just aspirational—it is achievable.

We hope that established journals in the fields of biology, life sciences, medicine, and pharmacology at MDPI will continue to serve as a communication platform for innovative ideas regarding prevention and treatment.

 “Trends in Tuberculosis Incidence and Mortality in South Africa and Bulgaria (2000–2023): The Impact of Income, Poverty, Unemployment, and Universal Health Coverage”
by Siyabonga Kave, Joana Simeonova, Antoniya Yanakieva, Alexandrina Vodenitcharova, Denisha Govender, Yandisa Sikweyiya and Nelisiwe Khuzwayo
Epidemiologia 2026, 7(2), 39; https://doi.org/10.3390/epidemiologia7020039

“Humoral Immune Activation Against Mycobacterium avium subsp. paratuberculosis Through Oral Immunization with Engineered Salmonella”
by Azar Motamedi Boroojeni, Nikoo Veiskarami, Elena Rita Simula, Leonardo Antonio Sechi and Abdollah Derakhshandeh
Bacteria 2025, 4(3), 47; https://doi.org/10.3390/bacteria4030047

“History of Pulmonary Tuberculosis Accelerates Early Onset and Severity of COPD: Evidence from a Multicenter Study in Romania”
by Ramona Cioboata, Silviu Gabriel Vlasceanu, Denisa Maria Mitroi, Ovidiu Mircea Zlatian, Mara Amalia Balteanu, Gabriela Marina Andrei, Viorel Biciusca and Mihai Olteanu
J. Clin. Med. 2025, 14(17), 5980; https://doi.org/10.3390/jcm14175980

“Integration of AI and ML in Tuberculosis (TB) Management: From Diagnosis to Drug Discovery”
by Sameeullah Memon, Shabana Bibi and Guozhong He
Diseases 2025, 13(6), 184; https://doi.org/10.3390/diseases13060184

“Three-Dimensional-Printed Isoniazid Chewable Gels for On-Demand Latent Tuberculosis Treatment in Children”
by Amanda de O. E. Moreira, Lêda Maria S. Azevedo Neta, Márcia Pietroluongo, Ana Paula dos S. Matos, Beatriz B. Correa, Beatriz H. Ortiz, André da S. Guimarães, Marcio Nele, Carollyne M. Santos, Ana Elizabeth C. Fai et al.
Pharmaceutics 2025, 17(5), 658; https://doi.org/10.3390/pharmaceutics17050658

“Prevalence and Associated Factors of Latent Tuberculosis Infection Among Healthcare Workers in a Mexican Tertiary Care Hospital”
by José Ángel Hernández-Mariano, Mónica Alethia Cureño-Díaz, Verónica Fernández-Sánchez, Estibeyesbo Said Plascencia-Nieto, Dulce Milagros Razo-Blanco-Hernández, Claudia Vázquez-Zamora, Víctor Hugo Gutiérrez-Muñoz, Beatriz Leal-Escobar, Erika Gómez-Zamora and Yanelly Estrella Morales-Vargas
Diseases 2025, 13(6), 173; https://doi.org/10.3390/diseases13060173

“The Complex Relationship Between Tuberculosis and Hyperglycemia”
by Michelle Byers and Elizabeth Guy
Diagnostics 2024, 14(22), 2539; https://doi.org/10.3390/diagnostics14222539

“The Role of mTOR in Mycobacterium tuberculosis Infection”
by Ami Patel, Lannhi Nguyen, Christina Shea, Sunjum Singh and Vishwanath Venketaraman
Biomedicines 2024, 12(10), 2238; https://doi.org/10.3390/biomedicines12102238

“Tuberculosis-Induced Immune-Mediated Necrotizing Myopathy: A Challenging Case Scenario in a Non-Endemic Country”
by Agnese Colpani, Davide Astorri, Andrea De Vito, Giordano Madeddu, Sandro Panese and Nicholas Geremia
Reports 2024, 7(4), 82; https://doi.org/10.3390/reports7040082

“Adherence to Short-Duration Treatment (3HP) for Latent Tuberculosis among International Migrants in Manaus, Amazonas: Evaluation of the Efficacy of Different Treatment Modalities”
by Yan Mathias Alves, Thaís Zamboni Berra, Sonia Vivian de Jezus, Vânia Maria Silva Araújo, Jair dos Santos Pinheiro, Lara Bezerra de Oliveira de Assis, Marvis Canelonez, Daniel Souza Sacramento, Freddy Perez, Ethel Leonor Noia Maciel et al.
Microorganisms 2024, 12(8), 1629; https://doi.org/10.3390/microorganisms12081629

“A Multidisciplinary Approach to the Management of Eales Disease: A Case Report and Review of the Literature”
by Maria Filoftea Mercut, Oana Maria Ică, Cornelia Andreea Tănasie, Răzvan Mercuț, Carmen Luminița Mocanu, Andreea Mihaela Nicolcescu and Ciprian Danielescu
J. Pers. Med. 2024, 14(3), 235; https://doi.org/10.3390/jpm14030235

“Mycobacterium tuberculosis Deficient in PdtaS Cytosolic Histidine Kinase Displays Attenuated Growth and Affords Protective Efficacy against Aerosol M. tuberculosis Infection in Mice”
by Kelly A. Prendergast, Gayathri Nagalingam, Nicholas P. West and James A. Triccas
Vaccines 2024, 12(1), 50; https://doi.org/10.3390/vaccines12010050

“Novel Therapeutic Agents and Innovative Delivery Systems Against Infectious Diseases” Guest Editor: Dr. Sara Consalvi Submission deadline: 30 June 2026	“Genomic Epidemiology & Drug Resistance in Mycobacterium tuberculosis” Guest Editors: Dr. Benson Kidenya and Dr. Gerald Mboowa Submission deadline: 30 June 2026
“Mycobacterial Infections and Human Disease: Emerging Mechanisms and Therapeutic Strategies/Boundaries” Guest Editors: Dr. Sameer Tiwari, Dr. Ashutosh Tripathi and Prof. Dr. Shahid Umar Submission deadline: 1 August 2026	“Recent Advances in Molecular and Cellular Approaches to Tuberculosis Pathogenesis, Treatment and Prevention” Guest Editor: Dr. Selvakumar Subbian Submission deadline: 20 August 2026
“Personalized Medicine in Epidemiology and Infectious Diseases” Guest Editors: Prof. Dr. Takalani Grace Tshitangano and Prof. Dr. Daniel Ter Goon Submission deadline: 20 September 2026	“Biomolecules in Mycobacterial Pathogenesis, Host–Pathogen Interactions, and Antimicrobial and Therapeutic Approaches” Guest Editor: Dr. Cinzia Marianelli Submission deadline: 31 December 2026

We are delighted to share Notable Perspectives Papers from the Journal of Clinical Medicine (JCM, ISSN: 2077-0383). These selected papers have drawn significant attention and cover our 12 sections, including but not limited to respiratory medicine, nephrology & urology, and nuclear medicine & radiology. We sincerely thank our Editorial Board Members for their valuable contributions, and we invite researchers from a wide range of clinical and research backgrounds to read these articles.

1. “Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI”
by Polat Goktas and Andrzej Grzybowski
J. Clin. Med. 2025, 14(5), 1605; https://doi.org/10.3390/jcm14051605
Full text available online: https://www.mdpi.com/2077-0383/14/5/1605

2. “Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment”
by Pankaj Garg, Siddhika Pareek, Prakash Kulkarni, David Horne, Ravi Salgia and Sharad S. Singhal
J. Clin. Med. 2024, 13(21), 6537; https://doi.org/10.3390/jcm13216537
Full text available online: https://www.mdpi.com/2077-0383/13/21/6537

3. “Advancing Clinical Practice: The Potential of Multimodal Technology in Modern Medicine”
by Yaara Artsi, Vera Sorin, Benjamin S. Glicksberg, Girish N. Nadkarni and Eyal Klang
J. Clin. Med. 2024, 13(20), 6246; https://doi.org/10.3390/jcm13206246
Full text available online: https://www.mdpi.com/2077-0383/13/20/6246

4. “New Horizons of Artificial Intelligence in Medicine and Surgery”
by Valerii Luțenco, George Țocu, Mădălin Guliciuc, Monica Moraru, Iuliana Laura Candussi, Marius Dănilă, Verginia Luțenco, Florentin Dimofte, Oana Mariana Mihailov and Raul Mihailov
J. Clin. Med. 2024, 13(9), 2532; https://doi.org/10.3390/jcm13092532
Full text available online: https://www.mdpi.com/2077-0383/13/9/2532

5. “Application of Artificial Intelligence in Otology: Past, Present, and Future”
by Hajime Koyama, Akinori Kashio and Tatsuya Yamasoba
J. Clin. Med. 2024, 13(24), 7577; https://doi.org/10.3390/jcm13247577
Full text available online: https://www.mdpi.com/2077-0383/13/24/7577

6. “The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives”
by Matteo Marchetti, Jacopo Ferrari, Tommaso Vezzaro, Laura Masatti, Giulia Tasca, Tiziano Maggino, Roberto Tozzi, Carlo Saccardi, Marco Noventa and Giulia Spagnol
J. Clin. Med. 2024, 13(23), 7041; https://doi.org/10.3390/jcm13237041
Full text available online: https://www.mdpi.com/2077-0383/13/23/7041

7. “Kidney Damage in Pediatric Obesity: Insights from an Emerging Perspective”
by Gianmario Forcina, Margherita Luciano, Vittoria Frattolillo, Simona Mori, Noemi Monaco, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice and Anna Di Sessa
J. Clin. Med. 2024, 13(23), 7025; https://doi.org/10.3390/jcm13237025
Full text available online: https://www.mdpi.com/2077-0383/13/23/7025

8. “Hyperreflective Retinal Foci (HRF): Definition and Role of an Invaluable OCT Sign”
by Luisa Frizziero, Giulia Midena, Luca Danieli, Tommaso Torresin, Antonio Perfetto, Raffaele Parrozzani, Elisabetta Pilotto and Edoardo Midena
J. Clin. Med. 2025, 14(9), 3021; https://doi.org/10.3390/jcm14093021
Full text available online: https://www.mdpi.com/2077-0383/14/9/3021

9. “Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research”
by Pankaj Garg, Siddhika Pareek, Prakash Kulkarni, Ravi Salgia and Sharad S. Singhal
J. Clin. Med. 2024, 13(12), 3466; https://doi.org/10.3390/jcm13123466
Full text available online: https://www.mdpi.com/2077-0383/13/12/3466

10. “Controlled Mechanical Ventilation in Critically Ill Patients and the Potential Role of Venous Bagging in Acute Kidney Injury”
by Mark E. Seubert and Marco Goeijenbier
J. Clin. Med. 2024, 13(5), 1504; https://doi.org/10.3390/jcm13051504
Full text available online: https://www.mdpi.com/2077-0383/13/5/1504

11. “From Awake to Minimalist Spontaneous Ventilation Thoracoscopic Lung Surgery: An Ongoing Journey”
by Eugenio Pompeo
J. Clin. Med. 2025, 14(7), 2475; https://doi.org/10.3390/jcm14072475
Full text available online: https://www.mdpi.com/2077-0383/14/7/2475

12. “Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions”
by Alice De Bernardi, Cristina Bezzio, Michele Puricelli, Daniela Gilardi and Simone Saibeni
J. Clin. Med. 2025, 14(2), 590; https://doi.org/10.3390/jcm14020590
Full text available online: https://www.mdpi.com/2077-0383/14/2/590

13. “Balancing Ethics and Innovation: Can Artificial Intelligence Safely Transform Emergency Surgery? A Narrative Perspective”
by Belinda De Simone, Genevieve Deeken and Fausto Catena
J. Clin. Med. 2025, 14(9), 3111; https://doi.org/10.3390/jcm14093111
Full text available online: https://www.mdpi.com/2077-0383/14/9/3111

Journal of Clinical Medicine (JCM, ISSN: 2077-0383) is an open access journal, and all published articles are freely available for reading and download.  Video abstracts are welcomed as an effective way for authors to present their research findings in a vivid and intuitive format. This approach creates a high-quality audiovisual experience that overcomes the limitations of traditional paper-based presentations. We are pleased to share selected papers with video abstracts published in 2024 and 2025, which we hope will provide valuable insights and reliable references for your related research.

1. “Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets”
by Allison B. Reiss, Berlin Jacob, Aarij Zubair, Ankita Srivastava, Maryann Johnson and Joshua De Leon
J. Clin. Med. 2024, 13(7), 1881; https://doi.org/10.3390/jcm13071881
Full text available online: https://www.mdpi.com/2077-0383/13/7/1881

2. “Systematic Review of Platelet-Rich Plasma in Medical and Surgical Specialties: Quality, Evaluation, Evidence, and Enforcement”
by Eqram Rahman, Parinitha Rao, Hany Niamey Abu-Farsakh, Chirag Thonse, Imran Ali, Alice E. Upton, Shwetha Y. Baratikkae, Jean D. A. Carruthers, Ash Mosahebi, Nima Heidari et al.
J. Clin. Med. 2024, 13(15), 4571; https://doi.org/10.3390/jcm13154571
Full text available online: https://www.mdpi.com/2077-0383/13/15/4571

3. “Diagnostic Methods for the Prenatal Detection of Cleft Lip and Palate: A Systematic Review”
by Ana Baeza-Pagador, Ana Tejero-Martínez, Lucas Salom-Alonso, Sara Camañes-Gonzalvo, Verónica García-Sanz and Vanessa Paredes-Gallardo
J. Clin. Med. 2024, 13(7), 2090; https://doi.org/10.3390/jcm13072090
Full text available online: https://www.mdpi.com/2077-0383/13/7/2090

4. “The Role of Scanning Electron Microscopy in the Evaluation of Conjunctival Microvilli as an Early Biomarker of Ocular Surface Health: A Literature Review”
by Mario Troisi, Salvatore Del Prete, Salvatore Troisi, Antonio Del Prete, Carlo Bellucci, Daniela Marasco and Ciro Costagliola
J. Clin. Med. 2024, 13(24), 7569; https://doi.org/10.3390/jcm13247569
Full text available online: https://www.mdpi.com/2077-0383/13/24/7569

5. “Effects of a Tele-Prehabilitation Program with Indirect Electrostimulation Compared to Home-Based Exercise in Patients Eligible for Lower Limb Arthroplasty: A Randomized Controlled Trial”
by Pamela Patanè, Vittoria Carnevale Pellino, Massimiliano Febbi, Caterina Cavallo, Fabrizio Gervasoni, Alessandro Gatti, Emanuele Caldarella, Francesca de Caro, Matteo Vandoni, Federica Manzoni et al.
J. Clin. Med. 2025, 14(4), 1356; https://doi.org/10.3390/jcm14041356
Full text available online: https://www.mdpi.com/2077-0383/14/4/1356

6. “Platelet Reduction after Transcatheter Aortic Valve Implantation: Results from the PORTRAIT Study”
by Federica Jiritano, Michele Di Mauro, Giuseppe Filiberto Serraino, Pasquale Mastroroberto, Elena Caporali, Enrico Ferrari, Mariusz Kowalewski, Roberto Scrofani, Leonardo Patanè, Giuseppe Visicchio et al.
J. Clin. Med. 2024, 13(6), 1579; https://doi.org/10.3390/jcm13061579
Full text available online: https://www.mdpi.com/2077-0383/13/6/1579

7. “Telemedicine/Telerehabilitation to Expand Enhanced Recovery After Surgery Interventions in Minimally Invasive Mitral Valve Surgery”
by Pietro Giorgio Malvindi, Maria Gabriella Ceravolo, Marianna Capecci, Stefania Balestra, Emanuela Cinì, Antonia Antoniello, Lucia Pepa, Antonella Carbonetti, Maurizio Ricci, Paolo Berretta et al.
J. Clin. Med. 2025, 14(3), 750; https://doi.org/10.3390/jcm14030750
Full text available online: https://www.mdpi.com/2077-0383/14/3/750

8. “The Utility of Three-Dimensional Printing in Physician-Modified Stent Grafts for Aortic Lesions Repair”
by Wiktoria Antonina Zasada, Hubert Stępak, Magdalena Węglewska, Łukasz Świątek, Jerzy Kluba and Zbigniew Krasiński
J. Clin. Med. 2024, 13(10), 2977; https://doi.org/10.3390/jcm13102977
Full text available online: https://www.mdpi.com/2077-0383/13/10/2977

9. “Fluid Overload in Children Following Hematopoietic Cell Transplant: A Comprehensive Review”
by Lama Elbahlawan, Amr Qudeimat, Ray Morrison and Alexandra Schaller
J. Clin. Med. 2024, 13(21), 6348; https://doi.org/10.3390/jcm13216348
Full text available online: https://www.mdpi.com/2077-0383/13/21/6348

10. “The Human Disharmony Loop: The Anatomic Source Behind Subacromial Impingement and Pain”
by Ketan Sharma, Jaicharan Iyengar and James Friedman
J. Clin. Med. 2025, 14(16), 5650; https://doi.org/10.3390/jcm14165650
Full text available online: https://www.mdpi.com/2077-0383/14/16/5650

Dear Colleagues,

As Editor-in-Chief of the Journal of Clinical Medicine (JCM, ISSN: 2077-0383), I am pleased to announce the winners of the 2026 Travel Awards. The award has been granted to Mr. Michael Klowak, a PhD student at the University of Toronto, Canada, and Ms. Nikoleta Bizymi, a Post-doctoral fellow at the National and Kapodistrian University of Athens, Greece.

Mr. Michael Klowak will be awarded CHF 800 to attend the 43rd International Symposium on Diabetes and Nutrition (June 15-18, 2026), to be held in Tarragona, Spain. Ms. Nikoleta Bizymi will be awarded CHF 800 to attend the ERS Congress 2026 (September 5-9, 2026), to be held in Barcelona, Spain.

As awardees, they will each receive an honorarium of CHF 800 and an electronic certificate.

With so many high-quality applicants, the evaluation process and final decision were challenging. We would like to thank all the applicants for submitting a wide and fascinating range of research topics.

On behalf of the assessment committee, I congratulate the winners on their accomplishments.

Prof. Dr. Kent Doi
Editor-in-Chief of JCM
On behalf of the JCM 2025 Travel Award Evaluation Committee

This webinar will spotlight idiopathic/progressive condylar resorption (ICR/PCR), a rare but significant disorder affecting the temporomandibular joint (TMJ). Once joint breakdown begins, ICR/PCR can progress and lead to severe dentofacial deformities and functional impairment. Early diagnosis and appropriate management of skeletal changes are therefore essential to prevent irreversible joint damage. As ICR/PCR can present with varying degrees of condylar resorption, treatment strategies may range from noninvasive therapies to minimally invasive procedures and surgical interventions, depending on disease severity.

In this webinar, international experts will present the current understanding and management strategies for ICR/PCR, with a focus on both noninvasive and surgical treatment modalities aimed at restoring mandibular function, reducing pain, and improving dentofacial aesthetics. Researchers, clinicians, and industry professionals are warmly invited to join this session to gain insights into the latest advances and future directions in ICR/PCR diagnosis and management.

Date: 10 April 2026 at 06:00 a.m. CST Asia | 07:00 a.m. JST| 08:00 a.m. AEST
Webinar ID: 810 7110 4460
Website: https://sciforum.net/event/JCM-23

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations made with academic institutional email addresses will be prioritized.

Unable to attend? Register anyway and we will let you know when the recording is available to watch online.

Register now for free!

Program:

Webinar Chair and Speakers:

• Prof. Eiji Tanaka (Chair), Tokushima University Graduate School of Biomedical Sciences, Japan;
• Prof. Dr. Kotaro Tanimoto, Hiroshima University Graduate School of Biomedical Sciences, Japan;
• Prof. Dr. Louis Mercuri, Rush University Medical Center, USA.

MDPI will attend the 12th Congress of the European Academy of Neurology (EAN 2026) as an exhibitor. This meeting will be held in Geneva, Switzerland, from 27 to 30 June 2026.

The European Academy of Neurology (EAN) Annual Congress gathers thousands of neurologists, scientists, educators, and healthcare professionals from around the world to discuss the latest developments in neurology. As one of the largest international events dedicated to brain and neurological health, the congress fosters scientific exchange, professional growth, and cross-sector collaboration.

The following open access journals will be represented:

• Brain Sciences;
• JCM;
• Neurology International;
• CTN;
• NeuroSci;
• Anesthesia Research;
• Antioxidants;
• Biomolecules;
• Diagnostics;
• Diseases;
• Medicina;
• Neuroglia;
• Sclerosis;
• Surgical Techniques Development;
• Epigenomes;
• Pathophysiology;
• Psychiatry International.

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #E63 and answering any questions you may have. For more information about the conference, please visit the following website: https://www.ean.org/congress2026.